GLOBAL LEADER

Cellect Biotechnology was founded in 2011 with a mission to become a global leader in the next generation of cellular therapies by developing innovative solutions for immune system regeneration.

INNOVATIVE SOLUTIONS

Achieving higher selectivity, greater specificity and decreased toxicity, Cellect envisions its products becoming an integral and essential part of Bone Marrow Transplantation (BMT), as well as integrated into many aspects of regenerative medicine.

ABOUT

OUR TECHNOLOGY

The Company’s platform technology is based on the game changing perception that stem-cells functional properties rather than appearance should be used to develop superior identification, selection and utilization of stem cells.

HEMATOPOIETIC STEM CELLS

Hematopoietic stem and progenitor cells (HSPC) are a small renewable pool of precursors that generate the immune and Hematopoietic systems throughout life
FIND OUT MORE

01

STEM CELL TRANSPLANTATION

Stem cell transplantation (SCT) is a medical procedure where stem cells reconstruct and replace damaged tissues and organs – a potential cure for a wide range of diseases and disorders.
FIND OUT MORE

02

GRAFT VERSUS HOST DISEASE

Graft versus Host disease (GvHD) is a common complication of allogeneic (non related) as well as Haploidentical (family member) stem cell transplantations
FIND OUT MORE

03

TECHNOLOGY PLATFORM

Cellect Biotechnology is based on a new concept of functional allocation, selection and use of stem cells.

PRECLINICAL DATA

Studies were performed to define the most relevant efector molecules, the concentrations and conditions for the murine studies.

STEM CELLS SELECTION KIT

An off the shelf medical device with a much shorter procedure and no special laboratory required that significantly reduces costs.

The CL10X replaces bespoke treatments with an off the shelf device

Procedure and hospitalization period of days instead of months.

Implement our technology in your existing laboratory environments

Our solution offers significant cost savings compared to existing treatments

Interested in our innovative technology?

BLOG

Latest News

For all the latest news and information about our company and our products, visit our blog.
14 Sep 2016

Cellect Receives Israeli Ministry of Health Approval to Initiate Phase I/II Clinical Trial in Leukemia Patients

Company’s innovative cell selection product may dramatically reduce bone marrow transplantation risks Patient enrollment expected to begin in the next few weeks Tel Aviv, Israel – September 13, 2016 – Cellect Biotechnology Ltd. (Nasdaq: APOP, TASE: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that the Company […]

Read more
01 Sep 2016

Cellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2016 Financial Results

Raised Gross Proceeds of $8.4 Million through Pricing of July U.S. Initial Public Offering   Tel Aviv, Israel – September 1, 2016 – Cellect Biotechnology Ltd. (NASDAQ: “APOP”, TASE: “APOP”), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the second […]

Read more

Interested in our innovative technology?

Contact Us